Afrezza: An inhaled approach to insulin delivery

Journal of the American Association of Nurse Practitioners
Laurie W FlemingCourtney S Davis

Abstract

The purpose of this article is to educate nurse practitioners about Afrezza. A comprehensive literature search was conducted using MEDLINE for clinical trial data. Information from the Centers of Disease Control and Prevention, World Health Organization, clinical guidelines, Food and Drug Administration labeling, briefings, and press releases was also utilized. Afrezza represents a promising noninjectable insulin delivery option for type 1 and type 2 diabetes mellitus. According to clinical trial evidence, it appears to be efficacious and comparable to currently available prandial insulin options, and based on current data, it appears to be a safe alternative to injectable insulin with high treatment satisfaction. Afrezza may offer an alternative for insulin naïve patients who are hesitant about initiating traditional insulin. It may cause less weight gain when compared to subcutaneous mealtime insulin with a more rapid absorption and elimination profile, but more long-term studies are needed. Afrezza is limited in type 1 diabetes to use in combination with basal insulin. It is not recommended in the treatment of diabetic ketoacidosis or for patients who smoke. It is contraindicated during hypoglycemic episodes, in chronic lung...Continue Reading

References

Feb 15, 2008·Endocrine Research·Michael StumvollTimon W van Haeften
Jun 7, 2008·The Diabetes Educator·Mary E LarkinDavid M Nathan
Jan 20, 2010·Diabetes Technology & Therapeutics·Mark Peyrot, Richard R Rubin
Feb 11, 2010·Journal of Diabetes Science and Technology·Robert AngeloPeter Richardson
May 14, 2010·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·Joshua J Neumiller, R Keith Campbell
Jun 3, 2010·The Annals of Pharmacotherapy·Joshua J NeumillerLindy D Wood
Apr 20, 2013·Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists·Alan J GarberUNKNOWN American Association of Clinical Endocrinologists

❮ Previous
Next ❯

Citations

Jul 30, 2015·Journal of Controlled Release : Official Journal of the Controlled Release Society·Moawia M Al-Tabakha
Nov 9, 2018·Frontiers in Endocrinology·Ignazio VecchioMariano Martini
Dec 29, 2020·Chemical Reviews·Stephanie FuchsMinglin Ma

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allergy and Asthma

Allergy and asthma are inflammatory disorders that are triggered by the activation of an allergen-specific regulatory t cell. These t cells become activated when allergens are recognized by allergen-presenting cells. Here is the latest research on allergy and asthma.